What is the recommended dosage and administration for a testosterone (T) patch in patients considering testosterone replacement therapy (TRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Patch Dosing and Administration

For testosterone replacement therapy using patches, start with a 2-4 mg/24-hour patch applied once daily to clean, dry, intact skin of the back, abdomen, upper arms, or upper thighs, rotating sites with each application. 1

Patient Selection Criteria

Before initiating testosterone patch therapy, confirm hypogonadism with:

  • Morning total testosterone drawn between 8-10 AM on at least 2 separate occasions showing frankly low levels 1
  • Free testosterone by equilibrium dialysis 1
  • Sex hormone-binding globulin level in patients with obesity 1
  • LH and FSH levels to distinguish primary from secondary hypogonadism 1

If secondary hypogonadism is confirmed, complete workup with serum prolactin, iron saturation, pituitary function testing, and MRI of the sella turcica to identify underlying causes before starting therapy. 1

Specific Patch Dosing Protocol

The standard testosterone 24-hour patch (Androderm) delivers 2 mg per 24 hours, with dosing range of 2-6 mg daily depending on response. 2

Application Instructions:

  • Apply to dry, intact skin of back, abdomen, upper thighs, or upper arms 2
  • Change patch daily, preferably at the same time 3
  • Rotate application sites to minimize skin irritation 2
  • Peak testosterone levels occur 6-8 hours after patch application 2, 1

Position in Treatment Algorithm

Transdermal testosterone gels are recommended as first-line therapy over patches due to better tolerability, with patches reserved for patients who cannot use gels. 1 The Endocrine Society prioritizes gels because patches frequently cause moderate to severe skin reactions and adherence problems. 4, 2

However, patches offer advantages over gels:

  • No risk of transference to partners or children through skin-to-skin contact 2, 1
  • Predictable absorption patterns compared to variable gel absorption 2
  • Reproduce physiological diurnal testosterone rhythm 3

The main limitations are skin rash/irritation at application sites and poor patch adherence to skin. 2

Monitoring Requirements

Measure testosterone levels 2-3 months after initiating patch therapy or any dose change, then every 6-12 months once stable levels are confirmed. 1

For patches specifically:

  • Testosterone can be measured at any time, though peak values occur 6-8 hours after application 2, 1
  • Target mid-normal testosterone range (500-600 ng/dL) 2
  • Monitor hematocrit/hemoglobin for erythrocytosis (occurs in 2.8-17.9% depending on dose) 1
  • Check PSA and perform prostate examination 1
  • Assess lipid panel 1

Safety Considerations

The FDA warns of possible increased cardiovascular risk with all testosterone preparations, though patches may carry lower risk than intramuscular injections. 1 Some evidence suggests intramuscular injections are associated with greater risk of cardiovascular events, hospitalizations, and deaths compared with transdermal preparations. 2

Patches carry significantly lower erythrocytosis risk than intramuscular injections. 1 The dose-dependent nature of erythrocytosis with transdermal preparations allows for easier dose adjustment compared to long-acting injections. 2

Testosterone replacement increases prostate volume to levels equivalent to eugonadal men but does not typically worsen voiding symptoms or cause urinary retention at higher rates than placebo. 1

Duration of Therapy

Continue testosterone replacement until clinical reassessment indicates otherwise, as replacement therapy is usually life-long for classical hypogonadism. 5 For age-related hypogonadism, continue as long as clinical symptoms that benefit from testosterone persist. 4

References

Guideline

Testosterone Replacement Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Testosterone therapy--what, when and to whom?

The aging male : the official journal of the International Society for the Study of the Aging Male, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.